XARELTO: payments to doctors
Payments that named XARELTO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $69.8M
- Providers
- 156,709
- Transactions
- 1,082,309
- Average per transaction
- $64
The per-transaction average — $64 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 156,709 providers the average total is $445, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $68,071,435 | 97.6% |
| Janssen Scientific Affairs, LLC | $1,111,352 | 1.6% |
| Janssen Research & Development, LLC | $449,365 | 0.6% |
| Bayer | $127,814 | 0.2% |
| Actelion Pharmaceuticals US, Inc. | $631 | 0.0% |
| Biosense Webster, Inc. | $75 | 0.0% |
| Johnson & Johnson Vision Care, Inc. | $21 | 0.0% |